TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06205394

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT05610358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone application
Description: In this study, the investigators will provide smartphone application based 12-week pulmonary or cardiac rehabilitation program to patients with chronic respiratory or cardiovascular diseases.
Study: NCT06257537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sustained Acoustic Device with 2.5% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Acoustic Device with 0% Diclofenac Patch
Description: Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5% Diclofenac Patches
Description: Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SAM Patch
Description: Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.
Study: NCT05229835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating and exercise
Description: We apply time restricted eating, exercise alone and combined

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating and exercise
Description: We apply time restricted eating, exercise alone and combined

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating and exercise
Description: We apply time restricted eating, exercise alone and combined
Study: NCT05952258

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic stimulation
Description: The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Magnetic stimulation
Description: The sham arm will receive up to 5% intensity at each treatment session
Study: NCT05175274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5mg/tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT05794737

Intervention type: BIOLOGICAL
Intervention: Immunohistochemical staining
Description: Staining of Colorectal Carcinoma tissue sections by monoclonal antibodies against human Inhibin Beta A by immunohistochemical procedures.
Study: NCT06199232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+targeted therapy+PD-1 inhibitor
Description: HAIC regimen: doublet or triplet regimen based on the response and adverse events occurred in the previous standard treatment (depended on the decision of researchers)-oxaliplatin (85 mg/m2, split into d1 and d2, 0-2h,) and 5-fluorouracial (2g/m2, split into d1 and d2, 2-24h)/ oxaliplatin (65 mg/m2, 0-2h, d1), irinotecan (100 mg/m2, 0-2h, d2), and 5-fluorouracial (2g/m2, split in d1 and d2, 2-24h), repeated every 4 weeks; drug-eluting TACE will be performed at 3rd-4th cycles if the lesions in liver is abundant with blood supply.~Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.~Cetuximab (Group A, KRAS/NRAK/BRAF/EGFR wide type and interrupt cetuximab more than 3 months): 500 mg/m2, intravenous drip before HAIC, q4w.~Fruquintinib (Group B, KRAS/NRAS/BRAF/EGFR mutation type and wide type but treated with cetuximab in last 3 months): 3 mg/d, d3-23, then suspend for 1w.
Study: NCT04684368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of CSF and blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of CSF and blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SC) or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given subcutaneously (SC) or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Given IV or orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo PBSC transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo WVSCI radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second-Look Surgery
Description: Undergo second-look surgery if needed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second-Look Surgery
Description: Undergo second-look surgery if needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study: NCT06049173

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative extra-abdominal pressure (NEXAP)-based lung recruitment maneuver
Description: The ventilator mode was changed from SIMV to PSV before LRM. After that, the abdominal pressure cardiopulmonary resuscitation (CPR-LW100) instrument was adopted and adsorbed on the epigastrium of patients. The LRM was performed by pulling up (tension of 20-30 kg) and compressing downward (tension\<10 kg) alternately on the abdomen of the patients with a frequency of 12 times per minute to support and maintain breathing. The whole LRM procedure lasted for 3 minutes in total. After LRM, the ventilator mode was changed to its baseline settings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stepwise positive end-expiratory pressure (PEEP)-based lung recruitment maneuver
Description: The ventilator mode was changed from SIMV to PSV before LRM. After that, PEEP was increased gradually (every 3-5cmH2O per 30s) from baseline (5-8 cmH2O) to 20cmH2O. The PEEP level was maintained at 20cmH2O for 60s, followed by decrements to baseline PEEP (every 3-5cmH2O per 30s). After LRM, the ventilator was changed to the baseline settings.
Study: NCT05289752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implants in the mandible
Description: placement of two interforaminal dental implants in the canine region in the mandible

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implants in the mandible
Description: placement of two interforaminal dental implants in the canine region in the mandible

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: locator attachment and overdenture
Description: placement of locator attachment and insertion of mandibular overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: locator attachment and overdenture
Description: placement of locator attachment and insertion of mandibular overdenture
Study: NCT06335966

Intervention type: DEVICE
Intervention: Screening with swallowable esophageal cell-collection devices (SECD)
Description: All participants who enroll in this study and provide their consent will undergo screening with an FDA approved swallowable esophageal cell-collection device (SECD)
Study: NCT06289868

Intervention type: DIAGNOSTIC_TEST
Intervention: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
Description: Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM).

Intervention type: DIAGNOSTIC_TEST
Intervention: Access anti-HAV and Access anti-HAV IgM on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
Description: Samples will be tested by comparing Access anti-HAV assay results to final anti-HAV sample status, and Access anti-HAV IgM results to final anti-HAV IgM status, according to respective instructions for use (IFU) or study guide, as applicable, to determine to determine non-reactive (NR), reactive (R), Negative, Positive or Equivocal (EQ).~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).~For evaluation of the clinical performance of Access anti-HAV IgM assay, all clinical samples, except pre- and post-vaccinated patient samples, will be tested with the reference assays Abbott - ARCHITECT® HAVAb-IgM, DiaSorin - LIAISON® Anti-HAV IgM, and SIEMENS Healthineers Atellica IM® Hepatitis A IgM (aHAVM).

Intervention type: DIAGNOSTIC_TEST
Intervention: Access anti-HAV on the DxI 9000 Access Immunoassay Analyzer and CE-marked predicate assays
Description: All samples will be tested pre- and post-vaccination by comparing Access anti-HAV assay results to final anti-HAV status, according to respective instructions for use (IFU) or study guide, as applicable, to determine non-reactive (NR), initial reactivity, and repeat reactivity.~For evaluation of the clinical performance of Access anti-HAV assay, all clinical samples will be tested with the reference assays DiaSorin - LIAISON® Anti-HAV and SIEMENS Healthineers Atellica® IM Hepatitis A Total (aHAVT).
Study: NCT04919434

Intervention type: OTHER
Group type: OTHER
Intervention: IRECO
Description: During 5 days, women included in the study will have to only use personal care product distributed by the research team.
Study: NCT04960124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922
Description: Participants will receive JNJ-42847922 tablet as a single oral dose (Dose 1 or Dose 2 or Dose 3) on Day 1.
Study: NCT06086964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic diet.
Description: gluten and casein free diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic diet.
Description: gluten and casein free diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: specific physiotherapy developmental program according to the pre evaluation of gross motor status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: specific physiotherapy developmental program according to the pre evaluation of gross motor status.
Study: NCT06151626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual-reality based rhythmic skill training
Description: Participants wear VR headsets and Oculus Touch controllers and undergo rhythm skill training for a total of 35 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rhythmic skill training with visual feedback
Description: The rhythm skill training activities in this group are the same as the virtual reality-based system. Participants received 35 minutes of rhythm skill training presented through a computer interface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: strengthening group
Description: Participants receive an upper limb strengthening exercise program under the supervision of a therapist to ensure that the strengthening exercises are performed correctly. This includes: proprioceptive neuromuscular facilitation, resistance training, and tendon gliding exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breathing and muscle relaxation exercises
Description: 5 minutes of breathing and muscle relaxation exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breathing and muscle relaxation exercises
Description: 5 minutes of breathing and muscle relaxation exercises
Study: NCT05207241

Intervention type: OTHER
Intervention: provides guidance on gravitationally assisted breastfeeding
Description: Prior to the first breastfeeding after delivery, the guidance of gravitationally assisted breastfeeding will be provided. The primary breastfeeding position is advised to be the sitting position, supplemented by the lateral position with a time ratio of 4:1. The following guidance will also be given: (1) participating women breastfeed individually without using a breast pump; (2) massage their breasts 4 times a day for 15 minutes each time; (3) breastfeeding time is scientifically matched with infant's schedule; (4) alternative breastfeed, ensuring emptying one breast within 24 hours. Doctors follow up once a month via WeChat. Participants complete the questionnaires. A breast ultrasound will be performed every three months. The infant weight will be measured and recorded 6 months after breastfeeding.
Study: NCT04141514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic fasting
Description: fasting limited to daily 250 kcal during 3 days (day before chemotherapy, the D day of the chemotherapy and the day after chemotherapy)
Study: NCT05880407

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SERI osteotomy
Description: Correction of varus deformity of the 1st Metatarsal that is stabilized with Kirschnner wire
Study: NCT06151626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing and muscle relaxation exercises
Description: 5 minutes of breathing and muscle relaxation exercises
Study: NCT06005987

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OneTouch Reveal application
Description: Evaluate if compliance with glucose logging and percentage of in range glucoses changes with use of a mobile application instead of paper logging
Study: NCT05880407

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous osteotomy according to Chevron
Description: Correction of varus deformity by osteotomy stabilization with 2 screws inserted via dorsal percutaneous accesses to the 1st Metatarsal.
Study: NCT05556889

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a modified auriculotemporal nerve blockade
Description: Helix feet in front of the zygomatic arch is served as anatomy marks of auriculotemporal nerve block, and the modified auriculotemporal nerve blockade is implemented as follows: Zygomatic arch level, posterior to the superficial temporal artery, the vertical puncture depth is about 0.5 -1 cm, and 2 ml of local anesthetics are injected after withdrawing without blood.
Study: NCT03760614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Entinostat will be administered orally on days 1, 8, 15 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX will be administered intravenously (IV), into a vein, using a port-a-cath every 2 weeks.
Study: NCT04915014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sleeve gastrectomy with transit bipartition (SG +TB)
Description: In case of a first intention procedure, a typical sleeve gastrectomy is performed, calibrated on a 36 French bougie, stapling starting 4 to 6 cm from the pylorus. Antecolic gastroileal anastomosis is performed 250 cm from the ileocecal transition, on the antrum using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 120 cm from the ileocecal junction. Thus, alimentary limb is 130cm and common limb 120cm.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Description: A small gastric pouch (30 cc) is performed. Antecolic gastroileal anastomosis is performed 200 cm from the Treitz junction, using a linear stapler (45-mm gold cartridge) or hand-sewn (at least 3 cm wide on the stomach). Laterolateral enteroanastomosis is performed 50 cm from the Treitz junction. Thus, alimentary limb is 150cm and biliary limb 50cm.
Study: NCT05255926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-pentixafor
Description: All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq/kg body weight).
Study: NCT05556889

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional auriculotemporal nerve blockade
Description: Traditional auriculotemporal nerve blockade
Study: NCT05833711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Froniglutide
Description: SC Weekly Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Froniglutide
Description: SC Weekly Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC Weekly Injection
Study: NCT05255926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: PET/CT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.
Study: NCT04940949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF90103
Description: Lu AF90103 - powder for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF90103
Description: Lu AF90103 - powder for solution for infusion
Study: NCT05197140

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food: cooked 85% lean ground beef
Description: see arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food: Impossible Burger (R)
Description: see arm description

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food: Impossible Burger (R)
Description: see arm description
Study: NCT06100484

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Two-dimensional RV strain imaging will be performed by using three consecutive cardiac cycles of 2D images in the apical four-chamber view to assess RV-GLS
Study: NCT05871229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Photodynamic antibacterial dual-light device with a marker substance

Intervention type: OTHER
Group type: OTHER
Intervention: Standard treatment for peri-implantitis
Description: Standard treatment for peri-implantitis as per international, national and clinic guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment for peri-implantitis
Description: Standard treatment for peri-implantitis as per international, national and clinic guidelines
Study: NCT06113757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Signal Therapy provided by Dr.Biolyse device
Description: Before the application, the area where the electrodes will be cleaned with appropriate solutions. In addition, 500-1000 ml of isotonic serum will be supplemented according to your weight, just before the first electrical signal application during the day. Electrical signal will be applied to the lung and upper leg area for 90 minutes in the morning, noon, and evening on the first 3 days, 60 minutes in the morning and evening on the 4th and 5th days, to the lung and upper leg area. During your first hospitalization, blood will be drawn from you daily for 5 days and evaluated in terms of various biochemical parameters and detailed molecular analyzes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Support Treatment
Description: The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
Study: NCT06348953

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selective caries removal and conventional non-bioactive restorative system
Description: conventional dental restorative adhesive and resin based composite

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selective caries removal and bioactive restorative system
Description: bioactive dental restorative resin based system
Study: NCT06051851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200mg IV D1~1 cycle every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days
Study: NCT04940949

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - powder for solution for infusion